{
    "organizations": [],
    "uuid": "795e94b5afdc9f741dd611c2e26b3d1965ae237b",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/04/09/pr-newswire-regeneron-to-report-first-quarter-2018-financial-and-operating-results-and-host-conference-call-and-webcast-on-may-3-2018.html",
    "ord_in_thread": 0,
    "title": "Regeneron to Report First Quarter 2018 Financial and Operating Results and Host Conference Call and Webcast on May 3, 2018",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "TARRYTOWN, N.Y., April 9, 2018 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that it will report its first quarter 2018 financial and operating results on Thursday, May 3, 2018, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.\nConference Call Information\nTo access this call, dial (800) 708-4540 (U.S.) or (847) 619-6397 (International). A link to the webcast may be accessed from the 'Investors and Media' page of Regeneron's website at www.regeneron.com . A replay of the conference call and webcast will be archived on the Company's website and will be available for 30 days.\nAbout Regeneron Pharmaceuticals, Inc.\nRegeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to six FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye disease, heart disease, allergic and inflammatory diseases, pain, cancer, infectious diseases and rare diseases.\nRegeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite ® technologies, such as VelocImmune ® which produces optimized fully-human antibodies, and ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.\nFor additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.\nContact Information:\nInvestor Relations\nCorporate Communications\nManisha Narasimhan, Ph.D.\nHala Mirza\n914.847.5126\n914.847.3422\nmanisha.narasimhan@regeneron.com\nhala.mirza@regeneron.com\nView original content: http://www.prnewswire.com/news-releases/regeneron-to-report-first-quarter-2018-financial-and-operating-results-and-host-conference-call-and-webcast-on-may-3-2018-300625737.html\nSOURCE Regeneron Pharmaceuticals, Inc.",
    "published": "2018-04-09T17:30:00.000+03:00",
    "crawled": "2018-04-09T18:37:21.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "tarrytown",
        "april",
        "regeneron",
        "pharmaceutical",
        "nasdaq",
        "regn",
        "today",
        "announced",
        "report",
        "first",
        "quarter",
        "financial",
        "operating",
        "result",
        "thursday",
        "may",
        "financial",
        "market",
        "open",
        "company",
        "host",
        "conference",
        "call",
        "simultaneous",
        "webcast",
        "eastern",
        "time",
        "day",
        "conference",
        "call",
        "information",
        "access",
        "call",
        "dial",
        "international",
        "link",
        "webcast",
        "may",
        "accessed",
        "medium",
        "page",
        "regeneron",
        "website",
        "replay",
        "conference",
        "call",
        "webcast",
        "archived",
        "company",
        "website",
        "available",
        "day",
        "regeneron",
        "pharmaceutical",
        "regeneron",
        "nasdaq",
        "regn",
        "leading",
        "biotechnology",
        "company",
        "invents",
        "medicine",
        "people",
        "serious",
        "disease",
        "founded",
        "led",
        "year",
        "unique",
        "ability",
        "repeatedly",
        "consistently",
        "translate",
        "science",
        "medicine",
        "led",
        "six",
        "treatment",
        "numerous",
        "product",
        "candidate",
        "development",
        "homegrown",
        "laboratory",
        "medicine",
        "pipeline",
        "designed",
        "help",
        "patient",
        "eye",
        "disease",
        "heart",
        "disease",
        "allergic",
        "inflammatory",
        "disease",
        "pain",
        "cancer",
        "infectious",
        "disease",
        "rare",
        "disease",
        "regeneron",
        "accelerating",
        "improving",
        "traditional",
        "drug",
        "development",
        "process",
        "proprietary",
        "velocisuite",
        "technology",
        "velocimmune",
        "produce",
        "optimized",
        "antibody",
        "ambitious",
        "research",
        "initiative",
        "regeneron",
        "genetics",
        "center",
        "conducting",
        "one",
        "largest",
        "genetics",
        "sequencing",
        "effort",
        "world",
        "additional",
        "information",
        "company",
        "please",
        "visit",
        "follow",
        "regeneron",
        "twitter",
        "contact",
        "information",
        "investor",
        "relation",
        "corporate",
        "communication",
        "manisha",
        "narasimhan",
        "hala",
        "mirza",
        "view",
        "original",
        "content",
        "http",
        "source",
        "regeneron",
        "pharmaceutical",
        "inc"
    ]
}